42.17 USD
-2.19 (-4.94%)
42.4 USD
+0.23 (+0.55%)
EXEL gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. An interesting combination arises when we look at growth and value: EXEL is growing strongly while it also seems undervalued. These ratings would make EXEL suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year EXEL was profitable.
EXEL had a positive operating cash flow in the past year.
Each year in the past 5 years EXEL has been profitable.
EXEL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
EXEL's Return On Assets of 24.01% is amongst the best of the industry. EXEL outperforms 97.36% of its industry peers.
EXEL's Return On Equity of 31.37% is amongst the best of the industry. EXEL outperforms 97.74% of its industry peers.
EXEL has a Return On Invested Capital of 26.31%. This is amongst the best in the industry. EXEL outperforms 98.87% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for EXEL is significantly below the industry average of 18.22%.
The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(26.31%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROIC | 26.31% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
The Profit Margin of EXEL (29.63%) is better than 95.67% of its industry peers.
EXEL's Profit Margin has declined in the last couple of years.
The Operating Margin of EXEL (35.85%) is better than 97.55% of its industry peers.
EXEL's Operating Margin has declined in the last couple of years.
The Gross Margin of EXEL (96.63%) is better than 96.42% of its industry peers.
EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
The number of shares outstanding for EXEL has been reduced compared to 1 year ago.
Compared to 5 years ago, EXEL has less shares outstanding
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 12.92 indicates that EXEL is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 12.92, EXEL belongs to the best of the industry, outperforming 84.93% of the companies in the same industry.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.92 |
ROIC/WACC3
WACC8.78%
2.3 Liquidity
A Current Ratio of 3.75 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Current ratio of 3.75. This is comparable to the rest of the industry: EXEL outperforms 44.63% of its industry peers.
A Quick Ratio of 3.68 indicates that EXEL has no problem at all paying its short term obligations.
EXEL's Quick ratio of 3.68 is in line compared to the rest of the industry. EXEL outperforms 45.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 44.51% over the past year.
Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.93%.
EXEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.51% yearly.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
3.2 Future
EXEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.76% yearly.
EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.99% yearly.
EPS Next Y39.79%
EPS Next 2Y29.02%
EPS Next 3Y29.08%
EPS Next 5Y25.76%
Revenue Next Year7.88%
Revenue Next 2Y9.88%
Revenue Next 3Y11.62%
Revenue Next 5Y9.99%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 17.79, which indicates a rather expensive current valuation of EXEL.
94.73% of the companies in the same industry are more expensive than EXEL, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.34, EXEL is valued a bit cheaper.
EXEL is valuated correctly with a Price/Forward Earnings ratio of 13.69.
Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 96.61% of the companies in the same industry.
EXEL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.79 | ||
| Fwd PE | 13.69 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.05% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.61% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.5 | ||
| EV/EBITDA | 12.11 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
EXEL's earnings are expected to grow with 29.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.45
PEG (5Y)1.41
EPS Next 2Y29.02%
EPS Next 3Y29.08%
5. Dividend
5.1 Amount
EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
42.17
-2.19 (-4.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.38%
Inst Owner Change-0.35%
Ins Owners2.17%
Ins Owner Change-2.56%
Market Cap11.31B
Revenue(TTM)2.29B
Net Income(TTM)677.90M
Analysts76.3
Price Target45.9 (8.85%)
Short Float %7.68%
Short Ratio7.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)2.52%
PT rev (3m)0%
EPS NQ rev (1m)11.16%
EPS NQ rev (3m)22.97%
EPS NY rev (1m)7.89%
EPS NY rev (3m)9.42%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)0.63%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.79 | ||
| Fwd PE | 13.69 | ||
| P/S | 4.94 | ||
| P/FCF | 14.5 | ||
| P/OCF | 14.29 | ||
| P/B | 5.23 | ||
| P/tB | 5.39 | ||
| EV/EBITDA | 12.11 |
EPS(TTM)2.37
EY5.62%
EPS(NY)3.08
Fwd EY7.3%
FCF(TTM)2.91
FCFY6.9%
OCF(TTM)2.95
OCFY7%
SpS8.53
BVpS8.06
TBVpS7.82
PEG (NY)0.45
PEG (5Y)1.41
Graham Number20.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROCE | 33.48% | ||
| ROIC | 26.31% | ||
| ROICexc | 44.11% | ||
| ROICexgc | 46.12% | ||
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% | ||
| FCFM | 34.08% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 37.81% | ||
| Cap/Sales | 0.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 93.06% | ||
| Profit Quality | 115.03% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 | ||
| Altman-Z | 12.92 |
F-Score8
WACC8.78%
ROIC/WACC3
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y39.79%
EPS Next 2Y29.02%
EPS Next 3Y29.08%
EPS Next 5Y25.76%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.88%
Revenue Next 2Y9.88%
Revenue Next 3Y11.62%
Revenue Next 5Y9.99%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year54.05%
EBIT Next 3Y25.06%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
What is the valuation status for EXEL stock?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
What is the profitability of EXEL stock?
EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.
What are the PE and PB ratios of EXELIXIS INC (EXEL) stock?
The Price/Earnings (PE) ratio for EXELIXIS INC (EXEL) is 17.79 and the Price/Book (PB) ratio is 5.23.